Lost for over 100 years, World War 1 era US submarine found along with bomber that sank in same area in 1950
Live Events
USS F-1 Tragedy
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
In a historic deep-sea expedition off the coast of San Diego, researchers have captured stunning, never-before-seen imagery of the U.S. Navy submarine USS F-1 , which sank on December 17, 1917, following a fatal collision during a training exercise. The accident claimed the lives of 19 crew members, whose final resting place has now been thoroughly surveyed and documented using state-of-the-art underwater technology.The high-resolution images of the World War I-era submarine were taken during a joint research expedition conducted from February 24 to March 4, 2025, by the Woods Hole Oceanographic Institution (WHOI) and several interagency partners, including the U.S. Navy, the National Science Foundation (NSF), and the Naval History and Heritage Command (NHHC).Using advanced deep-sea imaging tools such as the human-occupied vehicle (HOV) Alvin and the autonomous underwater vehicle (AUV) Sentry, researchers successfully located the submarine more than 1,300 feet (400 meters) below the surface.The mission also captured detailed imagery of a U.S. Navy Grumman TBF Avenger torpedo bomber that crashed nearby during a training flight in 1950.'Advanced ocean technology and simple teamwork played a big part in delivering these new images,' said Bruce Strickrott, senior pilot of Alvin and manager of WHOI's Alvin Group. 'As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.'The discoveries were made during a scheduled training and engineering dive intended to test equipment and develop new deep-sea research techniques. Alongside the technology trials, the expedition served as a somber reminder of the risks faced by sailors past and present.'It was an incredibly exciting and humbling experience to visit these historically significant wrecks and to honor the sacrifice of these brave American Sailors,' said Brad Krueger, underwater archaeologist for the NHHC, who completed his first dive aboard Alvin to visit the F-1 site.The USS F-1, originally conducting a 48-hour performance test, was lost when it collided with the USS F-3 in dense fog. Only three crew members survived. More than a century later, the wreck has been found lying intact on its starboard side, remarkably preserved by the deep-sea environment.To honor the fallen, a remembrance ceremony was held aboard the research vessel Atlantis, where the names of the 19 lost sailors were read aloud, and a bell rang 19 times—once for each life lost.'The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered,' said Krueger. 'History and archaeology are all about people, and we felt it was important to read their names aloud.'Advanced imaging tools, including multi-beam sonar and high-resolution cameras, enabled the creation of 3D photogrammetric models of the submarine and bomber wrecks. These reconstructions provide not only educational and historical value but also serve as crucial training assets for future oceanographic missions.'We were careful and methodical in surveying these historical sites so that we could share these stunning images, while also maintaining the reverence these sites deserve,' said Anna Michel, NDSF chief scientist and co-lead of the expedition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
9 hours ago
- NDTV
Mounjaro: Everything You Need To Know About This Medication
Mounjaro is the brand name for tirzepatide, a prescription medication developed by Eli Lilly that is primarily used to treat type 2 diabetes in adults. It is a once-weekly injectable drug that helps manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Mounjaro is unique because it's the first medication approved that targets both these hormones, offering better blood sugar control and weight loss compared to existing GLP-1 receptor agonists. Recently, it has also gained attention for its significant weight-loss effects, even in people who are overweight or obese but do not have diabetes, though this use may vary by country and approval status. Keep reading as we discuss everything you need to know about this medication. Everything you need to know about mounjaro How it works Mounjaro helps lower blood glucose by stimulating insulin release when blood sugar is high and reducing the amount of sugar produced by the liver. It also slows down digestion, which reduces the speed at which sugar enters the bloodstream after eating. The GIP component may enhance how the body responds to insulin and help reduce appetite, leading to gradual, sustained weight loss in many users. Benefits Apart from effective blood sugar control, Mounjaro has shown significant benefits in weight management, with some clinical trials showing up to 20% body weight loss in participants. This makes it a promising option for people with type 2 diabetes and those struggling with obesity-related health issues. It may also lower the risk of cardiovascular events and improve cholesterol levels, though long-term studies are still underway. Possible side effects Like many medications, Mounjaro can come with side effects. Common ones include nausea, vomiting, diarrhoea, constipation, and loss of appetite, especially when starting the drug or increasing the dose. These symptoms often subside as the body adjusts. More serious but rare side effects include pancreatitis, gallbladder issues, kidney problems due to dehydration, and severe gastrointestinal issues. There is also a black box warning due to the risk of thyroid C-cell tumours, including medullary thyroid carcinoma, observed in animal studies so it's not recommended for people with a personal or family history of such conditions. Who should avoid it Mounjaro is not approved for use in people with type 1 diabetes, and those with a history of pancreatitis, gallbladder disease, or medullary thyroid carcinoma should avoid it. It's also not typically recommended during pregnancy or breastfeeding unless deemed absolutely necessary by a healthcare provider. Always consult a doctor to evaluate if it's the right fit. Administration and monitoring Mounjaro is injected subcutaneously (under the skin) once a week, usually in the thigh, stomach, or upper arm. It's important to monitor blood sugar levels, weight, and digestive symptoms during the course of treatment. Regular kidney function tests, liver function panels, and monitoring for any abdominal symptoms are advisable while on this medication. Mounjaro represents a breakthrough in diabetes and weight management due to its dual-hormone approach. However, it is not a quick fix. It works best when combined with lifestyle changes such as a balanced diet, regular physical activity, and close medical supervision. While its effects are promising, it's crucial to use it responsibly and only under medical guidance. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Time of India
a day ago
- Time of India
Rapidly spreading COVID variant triggers fresh warnings — these are the symptoms doctors urge you to track
A new COVID variant called NB.1.8.1 is spreading fast in the world. It was first found in China in January 2025. Now, it makes up 10% of all COVID samples globally, which is a big jump from 2.5% four weeks ago, as per reports. The CDC said they're in touch with other countries about this variant. So far, only 20 cases have been found in the US, so it's not on the CDC COVID tracker yet. Doctors say this new variant causes similar symptoms to the older ones. The main signs are a dry cough that stays for long, blocked or runny nose, and feeling very tired. You may also get fever, chills, sore throat, and pain in your body. Most people can still do their normal things, but they'll feel more tired than usual, as per HuffPost report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Loja de Penápolis faz promoção de azeites Azeites Saiba Mais Undo There's no proof that NB.1.8.1 causes worse sickness or more people going to the hospital or dying. It has some new mutations on the spike protein that may help it spread faster and avoid the immune system. That means your body might not stop the virus as well as before, as per WHO. Scientists think the vaccines will still protect you from serious illness. NB.1.8.1 comes from the Omicron JN.1 family, which the 2024-2025 vaccines are made to fight. Vaccines might not fully stop infection, but they still help prevent serious problems. Live Events If you're older, have health problems, or take immune-lowering medicines, you should get vaccinated if it's been over 6 months since your last dose. If you're young and healthy, you probably don't need another shot right now, as per the HuffPost report. Most people can get better by just resting at home and drinking lots of fluids. If you have fever or body pain, you can take acetaminophen or ibuprofen. Normally, you'll feel better in about a week. If you are older or have a weak immune system, talk to a doctor. Doctors may give you antiviral pills like Paxlovid or Molnupiravir. These medicines work best within 5 days after symptoms start. Go to the hospital if you have chest pain, can't wake up or stay awake, feel confused or dizzy. The biggest red flag is trouble breathing , get help immediately if this happens, as per the HuffPost report. FAQs Q1. Do I need the vaccine for this new variant? Yes, if you are old, sick, or got your last shot over 6 months ago. Q2. Is there a new COVID virus? Yes, the new COVID variant is called NB.1.8.1.
&w=3840&q=100)
First Post
a day ago
- First Post
Are American companies underreporting carbon emissions? Satellites offer a clue
New satellite data shows US oil and gas companies may be underreporting methane emissions by up to two-thirds, casting doubt on corporate climate disclosures. As federal oversight weakens under Trump-era rollbacks, researchers urge governments to adopt satellite-based monitoring to enforce transparency. read more New satellite data reveals that many American companies, especially in the oil and gas sector are underreporting their greenhouse gas emissions, raising doubts about the reliability of corporate self-disclosures. This discrepancy highlights the potential for satellite monitoring to become a critical tool in ensuring accurate climate reporting and enforcing environmental accountability. Recent academic research, including a study from King's College London, compared emissions detected by Climate Trace, a global initiative using over 300 satellites and thousands of sensors, with companies' publicly reported figures. STORY CONTINUES BELOW THIS AD Alarmingly, about 75 firms were found to be reporting only around a third of their actual methane emissions. Methane, a potent greenhouse gas with a warming effect 80 times that of carbon dioxide over 20 years, primarily leaks from oil and gas operations, making accurate reporting vital for climate mitigation efforts. More from World Big blow to Chinese plane-makers as Trump bars export of critical jet parts, technology This growing evidence of underreporting comes at a politically sensitive moment in the US, where the federal government under President Donald Trump rolled back numerous climate regulations and openly questioned the science of climate change. Meanwhile, some states, led by Democrats are pushing forward with their own climate disclosure laws to fill the regulatory void left by federal rollbacks. State-level initiatives in New York and California seek to mandate comprehensive emissions reporting, including scope 3 emissions from supply chains, in contrast to the diluted or frozen federal rules. These efforts face legal challenges but signal increasing pressure on companies to provide transparent climate data. Experts note that while many companies voluntarily disclose emissions and climate risks, standardised and enforceable reporting remains crucial for investors and policymakers. Satellite technology, currently more precise in detecting methane than carbon dioxide, offers a promising avenue for governments to independently verify emissions data. Researchers propose that authorities use satellite estimates as default emission figures, requiring companies to prove if their actual emissions are lower, a move that could drastically reduce underreporting and improve climate policy effectiveness. STORY CONTINUES BELOW THIS AD As states move ahead despite federal inaction and as investors grow more skeptical of inconsistent disclosures, satellite monitoring could play an essential role in holding companies accountable. The technology may well become a cornerstone of future climate transparency, particularly in the areas where political resistance and misinformation continue to cloud efforts to tackle global warming.
